Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF
- PMID: 29266564
- DOI: 10.1002/ejhf.1078
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF
Abstract
Aims: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined.
Methods and results: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P < 0.0001).
Conclusions: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
Keywords: Heart failure; Implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular fibrillation; Ventricular tachycardia.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.
Comment in
-
Sudden cardiac death following admission for acute heart failure: adding insult to injury.Eur J Heart Fail. 2018 Mar;20(3):533-535. doi: 10.1002/ejhf.1109. Epub 2018 Jan 4. Eur J Heart Fail. 2018. PMID: 29314460 No abstract available.
Similar articles
-
Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD).Heart Rhythm. 2021 May;18(5):785-792. doi: 10.1016/j.hrthm.2021.01.009. Epub 2021 Jan 16. Heart Rhythm. 2021. PMID: 33465514
-
Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.Heart Rhythm. 2016 Apr;13(4):852-9. doi: 10.1016/j.hrthm.2015.12.024. Epub 2015 Dec 25. Heart Rhythm. 2016. PMID: 26724489 Clinical Trial.
-
Ventricular arrhythmias and haemodynamic collapse during acute coronary syndrome: increased risk for sudden cardiac death?Eur J Prev Cardiol. 2024 Dec 23;31(18):2117-2124. doi: 10.1093/eurjpc/zwae074. Eur J Prev Cardiol. 2024. PMID: 38394335
-
Drug therapy for ventricular tachyarrhythmia in heart failure.Circ J. 2007;71 Suppl A:A90-6. doi: 10.1253/circj.71.a90. Circ J. 2007. PMID: 17587746 Review.
-
Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?Heart Fail Rev. 2016 Jul;21(4):455-62. doi: 10.1007/s10741-016-9525-z. Heart Fail Rev. 2016. PMID: 26762335 Review.
Cited by
-
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.Life (Basel). 2022 Dec 8;12(12):2062. doi: 10.3390/life12122062. Life (Basel). 2022. PMID: 36556427 Free PMC article. Review.
-
Effect of implantable cardioverter defibrillator on primary prevention of sudden cardiac death in high-risk patients.Am J Transl Res. 2023 Feb 15;15(2):1352-1359. eCollection 2023. Am J Transl Res. 2023. PMID: 36915722 Free PMC article.
-
Ventricular arrhythmias in patients with functional mitral regurgitation and implantable cardiac devices: implications of mitral valve repair with Mitraclip®.Ann Transl Med. 2020 Aug;8(15):956. doi: 10.21037/atm.2020.02.45. Ann Transl Med. 2020. PMID: 32953756 Free PMC article.
-
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).Am J Cardiol. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11. Am J Cardiol. 2018. PMID: 29731121 Free PMC article. Clinical Trial.
-
Wearable defibrillator to improve accuracy in selecting candidates to implantable defibrillator: A real-world experience.ESC Heart Fail. 2024 Dec;11(6):3993-3999. doi: 10.1002/ehf2.14840. Epub 2024 Aug 1. ESC Heart Fail. 2024. PMID: 39091044 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous